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ABSTRACT 
Background: Benefits of drug-eluting stents (DES) in percutaneous coronary 
intervention (PCI) are greatest in those at the highest risk of target vessel 
revascularization (TVR). While DES reduce restenosis, they cost more than bare metal 
stents (BMS), and necessitate prolonged dual antiplatelet therapy (DAPT) that increases 
costs, bleeding risk, and risk of complications if DAPT is prematurely discontinued. Our 
objectives were to assess if DES are preferentially used in those with higher predicted 
TVR risk, and to estimate whether lower use of DES (50% less DES use among patients 
with low predicted TVR risk) would be more cost-effective as compared with the existing 
pattern of DES use. 
Methods: We analyzed ~1.5 million PCI procedures in the NCDR CathPCI registry from 
Apr 2003 - Sept 2010. We estimated 1-year TVR risk assuming PCI with BMS using a 
previously validated prediction model. The main outcome measures were the rate of DES 
use and projected annual US societal costs at one year after PCI. We assessed the 
association between TVR risk with BMS DES use, and performed cost-effectiveness 
analysis of a lower use of DES (50% less DES use among patients with low predicted 
TVR risk) vs. existing DES use.  
Results: There was marked variation in physicians’ use of DES (range = 2-100%). DES 
use was relatively high across all categories of predicted TVR risk (73.9% in patients 
with TVR risk <10%, 78.0% in TVR risk 10-20%, and 83.2% in TVR risk >20%), with a 
modest correlation between predicted TVR risk and DES use (RR 1.005/1% increase in 
predicted TVR risk [95% CI = 1.005, 1.006]). Reducing DES use by 50% among the 
lowest risk patients was projected to lower US healthcare costs by $205 million/year 
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while increasing the overall TVR event rate by 0.5% (95% CI= 0.49%, 0.51%) in 
absolute terms. 
Conclusions: DES use in the U.S. varies widely among physicians, with only modest 
correlation to patients’ risk of restenosis.  Less DES use among patients with low risk of 
restenosis has the potential for significant cost savings for the US healthcare system, 
while minimally increasing restenosis events. 
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INTRODUCTION 
Percutaneous Coronary Intervention (PCI) is the most common cardiac procedure 
performed in the United States, being conducted >600,000 times per year.1 PCI was first 
introduced in 1979 as an alternative method of coronary revascularization to CABG 
surgery.2 Since then, PCI has gained in popularity and become widely accepted as a safe 
and effective treatment alternative for coronary artery disease (CAD). The introduction of 
coronary bare metal stents (BMS) marked a major turning point in the practice of 
interventional cardiology, which led to dramatic reductions in not only acute abrupt 
vessel closure, but also longer term in-stent restenosis (ISR).  However, with the 
implantation of a bare metal stents the overall rate of in-stent restenosis (ISR) still 
remained high — approximately 20-30% overall.3-6 Restenosis of the treated vessel seen 
after BMS implantation, typically results in renewed anginal symptoms and the need for 
repeat target vessel revascularization (TVR). Binary angiographic restenosis is defined as 
the re-narrowing of the vessel lumen to >50% occlusion, usually within 3–6 months after 
PCI.3,4 Clinical restenosis is characterized by recurrent angina pectoris requiring TVR.3,4  
The advent of drug-eluting stents (DES) in the year 2003 was a second major 
advance that revolutionized the field of interventional cardiology by achieving dramatic 
decrease in the incidence of restenosis. Although drug eluting stents are much more 
expensive than BMS, they are highly effective in reducing restenosis, with an estimated 
50-70% relative risk reduction in target vessel revascularization (TVR) rates, as 
compared to BMS. 7,8 These benefits led to their rapid adoption after 2003, with a 
precipitous drop in BMS stent use, such that by 2005, DES use in the US was nearly 
90%9-12, and have persistently remained above 80% despite their costs.9-11   
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The widespread use of DES has raised questions about cost-effectiveness of this 
expensive technology.13-19 While trial-based economic analyses show DES are cost-
effective from a societal perspective20,21, analysis from a payer’s (Medicare) perspective 
has shown that widespread DES use ultimately increased Medicare expenditures by $544 
million over 2-years.22  A more contemporary analysis of Medicare beneficiaries from 
2002-2006 found that the annual costs attributable to DES were a staggering $1.57 
billion.23 Additionally, DES require prolonged dual-antiplatelet therapy (DAPT) 24-26 
which not only add more costs, but also increases bleeding events.24,25,27 
Clinically, the benefit of DES is greatest among those at the highest risk for 
TVR.28-32  Work by Tu et al. suggested that patients’ TVR risk greatly impacted their 
benefit in terms of number needed to treat (NNT) to prevent TVR.29 Therefore, some 
have suggested that DES should be preferentially used for only the higher TVR risk 
lesions.28,29,32 Whether clinicians judiciously use DES with the clinical logic of 
maximizing their use in those with the greatest benefit is unknown.  
To determine current patterns of DES utilization as a function of TVR risk and the 
potential clinical and economic implications of more tailored DES use, we analyzed data 
from the National Cardiovascular Disease Registry® (NCDR). Specifically, we assessed 
1) variation in use of DES among U.S. physicians participating in NCDR; 2) whether 
predicted TVR risk with BMS is associated with DES use, and 3) the estimated clinical 
and economic consequences of lower DES use among patients with low TVR risk.  
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METHODS 
NCDR Population 
The NCDR CathPCI Registry, co-sponsored by the American College of 
Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions 
(SCAI), is the largest U.S. clinical registry of patients undergoing diagnostic cardiac 
catheterization and PCI. Details of the CathPCI Registry have been previously 
described.33  In brief, trained data abstractors at each participating hospital collect 
detailed baseline clinical characteristics, in-hospital care processes, and outcomes 
retrospectively via chart review using a standardized set of data elements and definitions, 
which are available at http://www.ncdr.com/WebNCDR/elements.aspx.33 Systematic data 
entry, quality assurance, and auditing programs are employed to ensure that only data 
meeting predetermined criteria for completeness and accuracy are entered into the 
database.33 
Data from 2,120,659 PCI admissions from 1,119 hospitals participating in the 
registry from April 1, 2003 to September 30, 2010 were initially included. To ensure a 
sample of patients who were “eligible” for both stent types, we then excluded patients 
receiving stents <2.25 mm and >4 mm in diameter for which DES were not available 
throughout the period of observation. We next developed a propensity-score model to 
predict DES (vs. BMS) use via logistic regression conditioned upon 46 demographic and 
clinical variables. After plotting the distribution of propensity-scores by stent type, we 
excluded patients falling into regions of non-overlapping propensity scores.  These were 
patients in whom either DES or BMS were used almost exclusively and the choice of 
using an alternative stent was not likely feasible. The remaining PCI admissions were 
included. For admissions where multiple PCIs were performed, we analyzed only the first 
PCI. The above inclusion and exclusion criteria are detailed in figure 1. 
 
 Figure 1: Inclusion and exclusion criteria 
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 93565 Both DES & BMS  
used
 32294 Maximum Stent  
Diameter > 4 mm 
 2163 Missing data (no TVR 
probability) 
 249715 outside of optimal PS 
range (0.075 to 0.925) 
 1506778 PCI Procedures 
 1756493 PCI Procedures 
 1758656 PCI Procedures 
 1790950 PCI Procedures 
 76649 Minimum Stent 
Diameter <2.5 mm 
 1867599 PCI Procedures 
 1961164 PCI Procedures 
 159495 No Stents used 
 2120659 PCI Procedures 
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Predicting Risk of TVR 
For each patient, we estimated the risk of TVR assuming treatment with BMS 
using a validated prediction model developed from the Massachusetts Data Analysis 
Committee (MassDAC) database (table 1). 34 This model incorporates socio-
demographic, clinical and angiographic variables to predict TVR and possesses superior 
discrimination as compared with the 3 commonly used variables of diabetes, vessel 
diameter and lesion length, which are all components of the MassDAC model (full model 
in table 1).34  
Table 1: MassDAC TVR risk prediction logistic model 
 Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
P value Odds 
Ratio 
95% CI 
Lower 
95% CI 
Upper 
Intercept -2.8867 0.1264 521.6982 <.0001    
Drug Eluting Stent -0.6418 0.0546 138.2324 <.0001 0.526 0.473 0.586 
Age <= 50 0.2913 0.0665 19.1988 <.0001 1.338 1.175 1.524 
Age >= 80 -0.3942 0.0752 27.5041 <.0001 0.674 0.582 0.781 
Diabetes 0.1443 0.0509 8.0324 0.0046 1.155 1.046 1.277 
Peripheral Vascular 
Disease 
0.2683 0.0649 17.0624 <.0001 1.308 1.151 1.485 
Hypertension 0.1471 0.0604 5.9270 0.0149 1.158 1.029 1.304 
Previous PCI <= 1 Yr 0.9331 0.1402 44.3217 <.0001 2.542 1.932 3.346 
Previous PCI > 1 Yr or 
Timing Unknown 
0.2597 0.0571 20.6589 <.0001 1.297 1.159 1.450 
NYHA Class II -0.1061 0.0782 1.8397 0.1750 0.899 0.771 1.048 
NYHA Class III -0.1073 0.0749 2.0560 0.1516 0.898 0.776 1.040 
NYHA Class IV -0.2120 0.0767 7.6327 0.0057 0.809 0.696 0.940 
Atypical Chest Pain 0.0213 0.1500 0.0202 0.8868 1.022 0.761 1.371 
Stable Angina 0.3403 0.1025 11.0255 0.0009 1.405 1.150 1.718 
Unstable Angina 0.2720 0.1002 7.3608 0.0067 1.313 1.078 1.598 
Non-STEMI 0.0871 0.1074 0.6575 0.4174 1.091 0.884 1.347 
STEMI -0.0515 0.1384 0.1386 0.7096 0.950 0.724 1.246 
Urgent Status 0.1623 0.0681 5.6883 0.0171 1.176 1.029 1.344 
Emergent or Salvage  0.6207 0.1177 27.8230 <.0001 1.860 1.477 2.343 
>= 2 Vessels w >= 70% 
Stenosis 
0.4765 0.0500 90.7346 <.0001 1.611 1.460 1.776 
Number of Lesions 
Treated 
0.1877 0.0363 26.7748 <.0001 1.206 1.124 1.295 
Device Diameter >= 
3mm 
-0.3908 0.0501 60.9505 <.0001 0.677 0.613 0.746 
Device Length >= 30mm 0.2795 0.0555 25.3876 <.0001 1.322 1.186 1.474 
* This model had good discriminatory ability (C statistic = 0.655) and good calibration  (Hosmer-Lemeshow 
P=0.90) without evidence of any over-fitting in a separate validation dataset. 
 
The distribution of TVR risk with BMS in the NCDR CathPCI patient population 
varied widely from 2-80% is shown in figure 2. 
Figure 2: Distribution of the predicted TVR risk. 
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Statistical Analysis 
Baseline clinical and demographic patient characteristics by groups of low, 
moderate and high TVR risk were compared using the chi-square test for categorical 
variables and Student’s t test for continuous variables.  TVR risk was categorized into 
three clinically relevant groups of low (<10%), moderate (10% to <20%) and high 
(≥20%).  We then compared the rates of DES use in low, medium and high TVR risk 
groups, and estimated the unadjusted association of TVR risk with DES use by means of 
modified Poisson regression.  Because this association might have changed after concerns 
regarding stent thrombosis led to declines in DES use after 2006, 35,36 we included an 
interaction term between time (before and after October 2006) and TVR risk on the 
outcome of DES use. 
To identify the variation in DES use among physicians that was not attributable to 
differences in patients’ TVR risk, we developed a multilevel Poisson regression model by 
including ‘physician’ as a random effect in the model of DES use, with predicted TVR 
risk as a covariate, and estimated the Median Rate Ratio (MRR) for receipt of DES for 
patients with similar predicted TVR risk treated by 2 random hospitals 37-39. Since 
physician level information was only available in version 4.0 of the NCDR CathPCI data, 
this analysis was restricted to PCIs performed between July 1st, 2009 to September 30th,  
2010 (n = 415,115).  
Finally, we estimated the economic and clinical impact of a hypothetical 
reduction in the rate of DES use among the low TVR risk patients who received DES 
within the US PCI population (~600,000 PCIs per year).1. For this analysis, we assumed 
that the distribution of TVR risk as well as the use of DES among groups of TVR risk 
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within the NCDR population was representative of that seen in the US PCI population.  
We used previously described assumptions 40 to estimate clinical outcomes and costs 
from the perspective of the US healthcare system, as detailed in the Appendix.  The 
model considered the cost of stents, the cost of repeat revascularization procedures for the 
treatment of restenosis (and their associated hospitalizations), and the cost of dual 
antiplatelet therapy after either DES or BMS. For patients whose PCI was performed 
electively, we assumed the duration of DAPT would be 1 month after BMS and 12 
months after DES 41,42.  However, for PCI in the setting of an acute coronary syndrome, 
we assumed that DAPT would be used for 1 year regardless of stent type 41,42. We 
modeled the uncertainty observed in real-world clinical practice around these 
assumptions used in estimating costs and TVR events by performing sampling-based 
probabilistic sensitivity analysis in which we executed the cost-effectiveness model 
repeatedly (1000 samples) for combinations of values sampled randomly from the 
probability density functions of the input factors known to vary in real clinical practice. 
In addition to probabilistic sensitivity analysis, we performed additional 
deterministic sensitivity analyses assuming alternate proportions of DES use with a 
‘lower use’ strategy only among patients at low TVR risk (i.e. from existing rates of DES 
use [74% - see results] to 0% DES use in 1% increments).  Finally, we assumed that 
clopidogrel was available in generic form at a cost of $1/day.   All analyses were 
conducted in SAS version 9.2 software (SAS Institute, Cary, NC) and TreeAge Pro 2011 
software (TreeAge Inc., Williamstown, MA). 
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RESULTS 
A total of 1,506,758 PCI admissions met the inclusion criteria for the analysis. 
(Appendix Figure 1).  Of these, 648,292 (43.0%) patients were predicted to be in the low 
TVR risk group, 659,838 (43.8%) in the moderate TVR risk group, and 198,628 (13.2%) 
in the high TVR risk group.  As expected, patients with a high predicted TVR risk were 
more likely to be of older age, male, with diabetes, chronic kidney disease, and prior PCI.  
(Table 2)  They were also more likely to present with stable angina rather than an 
unstable coronary syndrome. Lastly, they were more likely to have severe 3-vessel CAD, 
with smaller diameter and longer lesions. 
Table 2: Baseline demographic and clinical patient characteristics by low, moderate 
and high probability of TVR groups. 
Total TVR risk group 
  (n = 1,506,758) 
Low 
(n = 648,292) 
Moderate 
(n = 659,838) 
High 
(n = 198,628) P-Value 
Demographics and Admission  
     Patient Age * 64.96 ± 12.22 66.02 ± 12.39 64.44 ± 12.04 63.17 ± 11.92 < 0.001 
     Male Gender        998753 (66.28%) 414890 (64.00%) 448016 (67.90%) 135847 (68.39%) < 0.001 
     Race/Ethnicity 
          Caucasian 
          Black 
          Hispanic 
          Asian 
          Native American 
          Other 
  
1263730 (84.01%)
99692 (6.63%) 
48181 (3.20%) 
19178 (1.27%) 
4929 (0.33%) 
68576 (4.56%) 
  
548800 (84.80%)
40045 (6.19%) 
19095 (2.95%) 
7662 (1.18%) 
1845 (0.29%) 
29702 (4.59%) 
  
551233 (83.67%)
44736 (6.79%) 
21802 (3.31%) 
8770 (1.33%) 
2258 (0.34%) 
29984 (4.55%) 
  
163697 (82.53%)
14911 (7.52%) 
7284 (3.67%) 
2746 (1.38%) 
826 (0.42%) 
8890 (4.48%) 
< 0.001 
     Insurance Payer 
          Government 
          Commercial 
          HMO 
          None 
          Non U.S. Insurance 
  
830629 (55.16%) 
417538 (27.73%) 
163192 (10.84%) 
92991 (6.17%) 
1594 (0.11%) 
  
347832 (53.68%)
190276 (29.36%)
75164 (11.60%) 
34054 (5.26%) 
655 (0.10%) 
  
366041 (55.51%)
179987 (27.29%)
70024 (10.62%)
42692 (6.47%) 
708 (0.11%) 
  
116756 (58.82%)
47275 (23.81%)
18004 (9.07%) 
16245 (8.18%) 
231 (0.12%) 
< 0.001 
History and Risk Factors  
     Prior MI (>7 Days) 380599 (25.26%) 106300 (16.40%) 191620 (29.04%) 82679 (41.63%) < 0.001 
     Prior History of CHF 164873 (10.94%) 56043 (8.64%) 76133 (11.54%) 32697 (16.46%) < 0.001 
     Diabetes * 486189 (32.27%) 150000 (23.14%) 240944 (36.52%) 95245 (47.95%) < 0.001 
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Total TVR risk group 
  (n = 1,506,758) 
Low 
(n = 648,292) 
Moderate 
(n = 659,838) 
High 
(n = 198,628) P-Value 
     Prior History of 
Renal Failure 
90209 (5.99%) 28627 (4.42%) 42265 (6.41%) 19317 (9.73%) < 0.001 
     Cerebrovascular Disea
se 
179672 (11.93%) 62085 (9.58%) 83836 (12.71%) 33751 (16.99%) < 0.001 
     Peripheral Vascular Di
sease * 
182894 (12.14%) 38342 (5.91%) 92915 (14.08%) 51637 (26.00%) < 0.001 
     Chronic Lung Disease 260056 (17.26%) 103407 (15.95%) 115104 (17.44%) 41545 (20.92%) < 0.001 
     Hypertension * 1163297 (77.21%) 455151 (70.21%) 532579 (80.71%) 175567 (88.39%) < 0.001 
     History of Tobacco Us
e 
          Never 
          Former 
          Current 
  
574947 (38.16%) 
504736 (33.50%) 
426827 (28.33%) 
  
267742 (41.31%)
211654 (32.65%)
168781 (26.04%) 
  
242575 (36.77%)
223083 (33.81%)
194080 (29.42%) 
  
64630 (32.54%)
69999 (35.25%)
63966 (32.21%) 
< 0.001 
     Dyslipidemia 1110810 (73.73%) 448319 (69.16%) 500765 (75.90%) 161726 (81.43%) < 0.001 
     Family History of CA
D age <55 
355744 (23.61%) 147800 (22.80%) 158478 (24.02%) 49466 (24.91%) < 0.001 
     Prior PCI * 467484 (31.03%) 102630 (15.83%) 239491 (36.30%) 125363 (63.12%) < 0.001 
     Prior CABG * 253157 (16.80%) 58416 (9.01%) 140964 (21.37%) 53777 (27.08%) < 0.001 
     Last Creatinine 1.19 ± 0.92 1.14 ± 0.79 1.21 ± 0.94 1.31 ± 1.18 < 0.001 
     GFR (MDRD) ml/min 73.06 ± 30.20 73.82 ± 29.42 72.82 ± 30.57 71.38 ± 31.36 < 0.001 
Cardiac Status  
     CHF 
During Current Admissio
n 
159497 (10.59%) 60624 (9.35%) 72419 (10.98%) 26454 (13.32%) < 0.001 
     NYHA * 
          Class 1 
          Class 2 
          Class 3 
          Class 4 
  
459673 (30.51%) 
330706 (21.95%) 
395951 (26.28%) 
320122 (21.25%) 
  
194923 (30.07%)
151896 (23.43%)
163646 (25.25%)
137722 (21.25%) 
  
202028 (30.62%)
139249 (21.11%)
176539 (26.76%)
141890 (21.51%) 
  
62722 (31.59%)
39561 (19.92%)
55766 (28.09%)
40510 (20.40%) 
< 0.001 
     Cardiogenic Shock 36358 (2.41%) 12024 (1.85%) 17689 (2.68%) 6645 (3.35%) < 0.001 
     Admission Presentatio
n * 
          No Symptoms 
          Atypical Chest Pain 
          Stable Angina 
          ACS:Unstable Ang
ina 
          ACS:Non-STEMI 
          ACS:STEMI 
  
200248 (13.29%) 
106552 (7.07%) 
213836 (14.19%) 
460478 (30.56%) 
269461 (17.89%) 
256050 (16.99%) 
  
103667 (15.99%)
65126 (10.05%) 
82579 (12.74%) 
179086 (27.63%)
116844 (18.03%)
100928 (15.57%) 
  
78241 (11.86%)
35455 (5.37%) 
98574 (14.94%)
208976 (31.67%)
116609 (17.67%)
121937 (18.48%) 
  
18340 (9.23%) 
5971 (3.01%) 
32683 (16.46%)
72416 (36.46%)
36008 (18.13%)
33185 (16.71%) 
< 0.001 
Angiographic and PCI Procedure Characteristics  
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Total TVR risk group 
  (n = 1,506,758) 
Low 
(n = 648,292) 
Moderate 
(n = 659,838) 
High 
(n = 198,628) P-Value 
     PCI Status * 
          Elective 
          Urgent 
          Emergency 
          Salvage 
  
670147 (44.48%) 
559774 (37.16%) 
271934 (18.05%) 
4704 (0.31%) 
  
332654 (51.32%)
237197 (36.59%)
77088 (11.89%) 
1245 (0.19%) 
  
269566 (40.86%)
247221 (37.47%)
140500 (21.29%)
2495 (0.38%) 
  
67927 (34.20%)
75356 (37.94%)
54346 (27.37%)
964 (0.49%) 
< 0.001 
     DES used 1158534 (76.89%) 478779 (73.85%) 514600 (77.99%) 165155 (83.15%) < 0.001 
     Minimum lesion 
diameter (mm) * 
3.01 ± 0.42 3.13 ± 0.40 2.96 ± 0.41 2.80 ± 0.37 < 0.001 
     Total lesion length 
(mm) * 
27.75 ± 17.68 21.77 ± 12.00 30.23 ± 18.44 39.05 ± 22.51 < 0.001 
     Number of diseased 
vessels * 
                     0 
                     1 
                     2 
                     3 
  
65501 (4.35%) 
783617 (52.01%) 
406325 (26.97%) 
251315 (16.68%) 
  
39628 (6.11%) 
507330 (78.26%)
62276 (9.61%) 
39058 (6.02%) 
  
22412 (3.40%) 
245278 (37.17%)
244194 (37.01%)
147954 (22.42%) 
  
3461 (1.74%) 
31009 (15.61%)
99855 (50.27%)
64303 (32.37%) 
< 0.001 
 
*Indicates variables included in the MassDAC TVR risk prediction mode 
 
Physician Variation in DES Use 
 
 We found extensive variation in physician patterns of DES use (Figure 3). Among 
the 2715 physicians performing 415,115 PCI procedures (at least >75 procedures/year), 
DES use ranged from 2%-100%. The variation across physicians, as described by the 
MRR was 1.8, suggesting that if 2 patients, predicted to be at similar TVR risk, presented 
to 2 random interventionalists participating in NCDR, there was, on average, a 1.8-fold 
greater probability of receiving a DES with one physician as compared with another.  
Figure 3: Physician level variation in the use of DES. 
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X-axis shows the individual physicians (n=2715) in NCDR version 4 data performing > 
75 PCI annually. These physicians have been ranked in ascending order of rate of DES 
use, such that those using the least DES are to the left and those using the highest DES 
are to the right. Physician use of DES ranged from 2 to 100%. The median rate ratio for 
this physician level variation was 1.8, implying an almost 2 fold variation in the use of 
DES directly attributable to physician preference, even after adjusting for patient factors 
related to DES use. 
 
Relations between predicted TVR risk and DES use 
The median predicted TVR risk was 11% (IQR 8% to 16%, Figure 2).  DES use 
was 73.9% among those at a low risk for TVR, , 78.0% among those at moderate risk for 
TVR and 83.2% among those at the highest TVR risk (Table 1 and Figure 4). When 
analyzed as a continuous variable, there was a 0.53% (95% CI = 0.50%, 0.56%) relative 
increase in the rate of DES use for each 1% increase in the predicted risk of TVR with 
BMS.   In addition, despite an overall decline in DES use over time (30% decline in DES 
use after October 2006), the relationship between TVR risk and DES use was modest in 
both time periods (RR 1.0020 [95% CI 1.0016 to 1.0025] before October 2006 vs. RR 
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1.0086 [95% CI 1.0082 to 1.0089] after October 2006, interaction P-value < 0.01) 
(Figure 4). 
Figure 4: Rates of DES use over time 
 
The first set of bar graphs shows the rates of DES use in the overall population. The next 
two sets of bar graphs show rates of DES use before October 2006 (this date marks the 
date of the ‘stent thrombosis scare’ which led to a 30% decline in DES use in 2007).  
 
Potential Cost Implications of Lower DES Use Among Low Risk Patients 
 A 50% reduction in the use of DES only among those with the low risk of TVR 
was estimated to result in potential net savings of $204,654,000 per year in the US 
(Figure 3), or $34,109 per 100 PCIs performed, as compared with current practice. These 
estimated net savings accounted for an estimated increase in costs of repeat procedures 
due to TVR (absolute increase in TVR rate = 0.50%, 95% CI 0.49%-0.51%), which were 
estimated to cost $64,728,000, and an estimated decrease in costs resulting from a 
decrease in clopidogrel use only among the elective PCI patients) (Figure 5). 
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Figure 5: Cost-effectiveness of ‘Judicious DES use’ strategy vs. ‘Existing DES use’ 
strategy. 
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Cost-effectiveness analysis showed an incremental cost-effectiveness ratio of 
$68,230/TVR avoided when comparing ‘Existing DES use’ against the alternative of 
‘Judicious DES use’ (Figure 5).  In the 1000 NCDR samples generated by sampling-
based probabilistic sensitivity analysis, the incremental cost-effectiveness ratio for 
‘Existing use’ vs. ‘Judicious use’ strategy exceeded the $10,000/TVR avoided 
willingness-to-pay threshold in 98.3% of the 1000 trial replicates (Figure 6).  
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Figure 6: Incremental cost-effectiveness (A) and cost-effectiveness acceptability 
curve (B) of ‘Existing use strategy’ vs. ‘Judicious use strategy’ (base case) in the 
1000 NCDR samples generated by sampling-based probabilistic sensitivity analysis. 
 
Panel A: 
 
 
WTP threshold $10,000/TVR avoided 
Panel B: 
 
‘Existing use strategy’ vs. ‘Judicious use strategy’ (Base case) in the 1000 NCDR 
samples generated by sampling-based probabilistic sensitivity analysis.  
Panel A:  
X-axis shows incremental effectiveness (TVR events) of ‘Existing use strategy’ - 
‘Judicious use strategy’. Points to the left of ‘0’ indicate decreased efficacy (more TVR 
events with ‘Judicious use strategy’ vs. ‘Existing use strategy’). Y-axis shows 
incremental costs ‘Judicious use strategy’ - ‘Existing use strategy’. Points below ‘0’ 
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indicate costs saved from a ‘Judicious use strategy’. The ellipse represents the 95% 
confidence ellipse, and contains 95% of the simulations.   
Panel B: 
X-axis shows the willingness-to-pay threshold. The solid vertical line represents the 
$10,000/TVR avoided threshold. Values above this threshold are generally considered 
unfavorable. Y-axis shows the proportion of simulations that are cost-effective.  
The solid blue curve is the cumulative probability density function of the 1000 trial 
replicates. 98.3% of the 1000 trial replicates showed an incremental cost-effectiveness 
ratio for ‘Existing use’ vs. ‘Judicious use’ strategy that exceeded $10,000/TVR avoided. 
 
 
The projected impact of alternative rates of DES use among patients at low risk of 
TVR with BMS is shown in Figure 7.  As the rate of DES use among low risk patients 
decreases, the potential cost savings are projected to increase substantially with minimal 
change in clinical outcomes.  For example, use of only BMS among patients at low risk 
of TVR would be projected to reduce current healthcare expenditures by 
$409,317,379/year with only a 0.99% absolute increase in the risk of TVR at a population 
level. Finally, with the  assumption that the cost for dual antiplatelet therapy would 
decrease to $1/day (with the expected approval of generic clopidogrel in 2012), the 
estimated net cost savings with a 50% reduction in DES use in the low TVR risk group 
was projected at $127,950,000/year.   
Figure 7: Sensitivity of projected cost-savings to assumed reductions in DES use in 
low TVR risk patients. 
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X-axis shows the proportion by which DES use is reduced in the low TVR risk group 
patients who received a DES in NCDR. The first bar represents 100% BMS use in this 
low predicted TVR risk group, while the last bar represents ‘Existing use’ or 74% DES 
use in the low TVR risk group. Y-axis on the left shows the US annual costs saved 
($)/year in patients undergoing PCI and is represented by the light gray bars. Y-axis on 
the right shows the absolute increase in TVR event rate (%) and is represented by the 
black line.  
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DISCUSSION 
The present study demonstrates that in current US practice, DES use remains 
prevalent, even among patients at low risk to develop restenosis. There was also 
significant variation in the rate of DES use by individual physicians.  A reduction in DES 
use among patients at low risk for restenosis  was projected to be associated with 
substantial costs savings with only a  small increase in TVR events. 
The use of advanced medical technology such as DES remains an important 
driver of increasing healthcare costs in the US and worldwide. Groeneveld et al 14 
analyzed Medicare data on 2 million beneficiaries from 2002 to 2006 and found that the 
additional costs attributable to DES use were $1.57 billion annually.  Given the costs to 
patients and society of DES technology, and the potential risks of the requirement for 
long term DAPT after DES (increased bleeding with therapy, increased stent thrombosis 
with premature discontinuation), there appears to be an important opportunity to tailor 
DES use to those with the greatest potential to benefit and reduce its use in those with 
favorable outcomes after BMS alone. From an economic perspective, this study projected 
that adopting a strategy that reduced the current use of DES in those with the lowest 
predicted risk of TVR by 50% could be associated with cost savings of ~$200 million 
every year in the United States alone, even after accounting for a small increase (< 0.5%) 
in the need for subsequent PCI for restenosis – a relatively benign and stable condition. 
Collectively, these findings suggest that current DES utilization patterns offer an 
important opportunity to tailor therapy to patient risk and reduce costs to the healthcare 
system.  
 Several previous studies have compared the clinical benefits of DES vs. BMS 
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among patients across different levels of restenosis risk.  Tu and colleagues analyzed data 
from Ontario’s Cardiac Care Network and found that the benefits of DES were 
substantially greater in those patients with diabetes, small target vessels [<3 mm in 
diameter], and long lesions [stent length ≥20 mm] 31. The number needed to treat (NNT) 
to prevent one TVR event with the use of DES ranged from 10 to 27 in those individuals 
with 2 or more of these risk factor for TVR, while in those with fewer risk factors the 
effectiveness of DES did not differ significantly from that of BMS and the NNT ranged 
from 53 to 167.31 More recently, a post-hoc analysis from the HORIZONS-AMI trial of 
acute MI patients demonstrated that in patients at highest risk for restenosis, use of DES 
resulted in a marked reduction in TLR at 12 months, but that no differences in TLR at 12 
months were present between DES and BMS in patients at low risk for restenosis.30   The 
current study extends these previous findings by using national clinical  practice data to 
examine how DES are being utilized in relation to patient risk for restenosis, and to 
estimate how changes in practice could affect healthcare costs on a population level . 
The findings of this study also extend recent insights from the EVENT 
investigators who found that the ~25% reduction in DES use after the 2006 was 
accompanied by a small increase in clinical restenosis, but no differences in the rates of 
death or myocardial infarction.43 However, this decrease in DES use after 2006 led to 
substantial reductions in the cost of cardiovascular care of ~$400 per PCI patient. In this 
study, while reduced DES use after 2006 was associated with risk factors for restenosis, 
these associations were modest, implying that reductions in DES weren’t necessarily in 
low TVR risk patients. Our findings now build upon this concept and suggest that further 
reductions in DES use only among patients at low risk of TVR may translate into 
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additional cost savings with an even smaller impact on overall clinical TVR outcomes 
than that observed in the EVENT study.    
We found that the projected cost-savings associated with lower use of DES were 
extremely sensitive to the magnitude of reduction in DES use among low TVR risk 
patients, while estimated increases in TVR events were largely insensitive to these 
reductions. Changes in clinical practice patterns leading to even a small reduction in DES 
use in low risk patients may result in substantial cost savings. This begs the question of 
how to change clinical practice regarding the choice of DES versus BMS. The MassDAC 
TVR risk prediction model could potentially offer an evidence-based solution to this 
problem. The MassDAC model is freely available as an online tool 
(http://massdac.org/riskcalc/revasc) and could be used to prospectively inform clinicians 
and patients of patients’ TVR risk prior to stent implantation.44  Use of the model could 
not only promote evidence-based care but also shared decision-making with patients’ so 
that patients’ preferences for small reductions in TVR could be integrated with their 
desires to adhere to DAPT and its potential costs and bleeding risks.   
We purposefully selected to model a strategy of reducing DES by 50% in the low 
risk group, in order to give clinicians and patients the ability to exercise their judgment 
and preferences on a case-by-case basis, while setting a target goal that could potentially 
lead to substantial cost savings.  The intention was to illustrate the potential for costs 
savings without a significant increase in patient morbidity that could be achieved with a 
more selective and evidence-based approach to the stent selection than is currently 
observed, and without advocating a sweeping policy change that would limit both 
physician and patient autonomy.   
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This study should be interpreted in the context of several potential limitations. 
First, the discrimination of the model used to estimate predicted TVR risk was modest (c-
statistic = 0.66). However, this model had better discrimination than the more commonly 
applied risk factors of diabetes, vessel diameter and lesion length (0.66 vs. 0.60, 
p<0.0001) 34. In addition, model calibration, a metric for assessing a model’s ability to 
identify a low TVR risk group of patients, was  excellent (Hosmer-Lemeshow P=0.90).34  
Thus, the projections of the increase in TVR events with the lower DES use strategy 
among low risk patients and associated TVR costs are likely to be accurate. Next, we did 
not account for either the potential costs of major or nuisance bleeding or the potential 
ischemic benefits of prolonged DAPT, as these represent areas of uncertainty in the 
literature that are currently under investigation.45  Third, we did not have any assessment 
of patients’ preferences for DES. It is possible that many patients at low risk would prefer 
to accept the costs and risks of prolonged DAPT in exchange for a reduced risk of repeat 
procedures.  Such patients could still be among the 50% of low risk patients who receive 
DES in our proposed strategy.  Fourth, while our model of clinical and economic 
outcomes of PCI procedures was based on the best available clinical and economic data, 
the resulting projections cannot be directly verified using empirical data at present. 
Conclusions 
Although the benefits of DES are greatest among patients at the highest risk for 
restenosis, DES use is common even among those predicted to be at the lowest risk for 
TVR. Given marked variation in physicians’ DES use, a strategy of lower DES use 
among patients at low risk of TVR could present an important opportunity to reduce 
healthcare expenditures while preserving the vast majority of their clinical benefit.    
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APPENDIX A – Supplementary Materials 
Assumptions for Costing Methods 
The cost of a TVR event was $19,000 per episode in 2004 20,21,46. When inflated 
to US $2009 the cost of TVR was estimated to be $21,578. DES costs $1200 more than 
BMS (need reference the IMS survey), the cost of clopidogrel therapy was estimated 
using the average wholesale price (AWP) of clopidogrel in 2009 ($4.62 per day)47. The 
duration of clopidogrel therapy was assumed to be 12 months for DES patients and 1 
month for BMS patients undergoing elective PCI.48 Since clopidogrel is recommended 
for a year in patients with an acute coronary syndrome (ACS) undergoing PCI, the cost of 
clopidogrel was assumed to be equal in the ACS patients, irrespective of DES or BMS 
used.41,42 We also assumed an average of 1.5 stents used per PCI procedure (from 
NCDR), TVR rates as predicted by the MassDAC model (low risk group 7.32%; 
moderate risk group 13.98%; high risk group 26.09%), the cost of index PCI procedure in 
2009 US$ - $ 10,435.49 This was estimated from Medicare reimbursements to hospitals 
for 294,737 PCI procedures in year 2009 as a weighted average of 4 DRGs for PCI [DRG 
246 (PCI with DES With MCC, cost $16,702, 14.6% procedures), DRG 248 (PCI with 
BMS With MCC, cost $15,546, 6.7% procedures), DRG 247 (PCI with DES without 
MCC, cost $9,113, 59.9% procedures) and DRG 249 (PCI with BMS without MCC, cost 
$7,924, 18.7% procedures)]49  Thus, costs included direct costs to Payers (cost of 
procedures), and also societal costs (cost of clopidogrel), but not indirect costs – and 
hence referred to as a modified US societal perspective. Efficacy of DES vs. BMS for the 
outcome of TVR was assumed to be a relative risk of 0.57 as predicted by the 
MassDAC34 as well as prior studies of DES vs. BMS in real-world data50. All cost 
savings were estimated for a single PCI procedure in the overall NCDR population in the 
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‘Judicious DES use’ strategy as compared to the ‘Existing DES use’ strategy. Since 
600,000 PCI procedures are performed annually in the US currently1, these cost savings 
were multiplied by a factor of 600,000 to estimate the yearly cost savings in the US. 
Assumptions for Probabilistic Sensitivity Analysis Methods 
To model the uncertainty observed in real-world clinical practice around some of 
the assumptions used in estimating costs and TVR events, we performed a sampling-
based probabilistic sensitivity analysis in which we executed the above cost-effectiveness 
model repeatedly (for 1000 NCDR samples) for combinations of values sampled 
randomly from the probability density functions of the following input factors known to 
vary in real clinical practice and would affect the cost-effectiveness of DES in this setting 
- TVR risk in NCDR (normal distribution, low risk group μ= 7.32% and σ =1.61%; 
moderate risk group μ= 13.98% and σ =2.75%; high risk group μ= 26.09% and σ 
=5.90%), number of DES used per case in NCDR (normal distribution, μ= 1.5 stents and 
σ =0.82 stents, distribution trimmed to not allow ‘negative’ number of stents), the cost of 
index PCI procedure in 2009 US$ - $10,435 (lognormal distribution), the cost of TVR 
inflated to US $ 2009 - $ 21,578 (lognormal distribution), monthly cost of clopidogrel at 
$4.62/day (or $138.6/month) in 2009 (lognormal distribution), the additional cost of a 
DES in 2009 over a BMS $1200/stent (lognormal distribution) and the duration of 
clopidogrel therapy with DES use (normal distribution, , μ= 12 months and σ =0.5 
months, truncated at 12 months). The duration of clopidogrel therapy with BMS use in an 
elective PCI case was assumed to be 1 month, while it was assumed to be again 12 
months (normal distribution, μ= 12 months and σ =0.5 months, truncated at 12 months) 
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when BMS was used in the setting of an acute coronary syndrome (unstable angina, non-
STEMI and STEMI PCI procedures).41,42 
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APPENDIX B - SAS Program Code 
 
/*311P*/ 
libname v3 'S:\acc-ncdr\cathpci\data\v3\analysis\crosswalk'; 
options fmtsearch=(v3) nofmterr; 
libname tvr 'S:\acc-ncdr\Analysis\2011\311P\Data'; 
%let output=S:\acc-ncdr\Analysis\2011\311P\Output; 
 
proc means data=tvr.final; 
where phat_group=1; 
var phat_bms; 
run; 
 
proc means data=tvr.final; 
where phat_group=2; 
var phat_bms; 
run; 
 
proc means data=tvr.final; 
where phat_group=3; 
var phat_bms; 
run; 
 
/*get total stent leng and min dia*/ 
proc sql; 
create table desbms as select UIdPatStay, Nattempt, DevDiam, DevLen, ICDevType 
from v3.icdev 
where ICDevType in  
; 
quit; 
 
proc sql; 
create table desbms2 as select unique(uidpatstay),nattempt,min(devdiam) as 
min_diam,max(devdiam) as max_diam, 
sum(devlen) as total_length, sum(ICDevType=11) as num_des, 
sum(icdevtype=3) as num_bms 
from desbms 
group by uidpatstay 
; 
quit; 
 
proc sql; 
create table desbms3 as select * 
from v3.analysis as a left join desbms2 as b on a.uidpatstay=b.uidpatstay 
; 
quit;  
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data tvr.data; 
set desbms3; 
/*number dz vessels*/ 
/*indicator for sig vessel dz*/ 
if lmpr>=50 then do; 
 if rcapr>=70 then num_dis_ves=3; 
 else num_dis_ves=2; 
end; 
else if lmpr<70 then do; 
 num_dis_ves=(pladpr>=70 or mdladpr>=70) + (rcapr>=70) + (circpr>=70 or 
rampr>=70); 
end; 
num_dis_ves_svg=num_dis_ves+(PLADgPr>=70 or MDLADgPr>=70 or CIRCgPr>=70 
or RCAgPr>=70 or RAMgPr>=70); 
 
if prpci=1 then do; 
 priorpcitime=datepart(procdt)-datepart(prpcidt); 
end; 
 
/*full model probabilities*/ 
g=-2.8867+ (.2913*(age<=50)) + (-.3942*(age>=80)) + (.1443*diabetes) + (.2683*pvd) 
+ (.1471*hypertn) + (.9331*(prpci=1 and 0<=priorpcitime<=365)) + (.2597*(prpci=1 and 
(priorpcitime<0 or priorpcitime>365))) 
+ (-.1061*(ClassNYH=2)) + (-.1073*(ClassNYH=3)) + (-.2120*(ClassNYH=4)) + 
(.0213*(admsxpre=2)) 
+ (.3403*(admsxpre=3)) + (.2720*(admsxpre=4)) + (.0871*(admsxpre=5)) + (-
.0515*(admsxpre=6)) 
+ (.1623*(PCIStat=2)) + (.6207*(PCIStat>=3)) + (.4765*(num_dis_ves>=2)) + 
(.1877*Ndilated) +  
+ (-.3908*(min_diam>=3)) + (.2795*(total_length>=30)); 
phat_bms=exp(g)/(1+exp(g)); 
 
g_des=-2.8867 + (-.6418) + (.2913*(age<=50)) + (-.3942*(age>=80)) + (.1443*diabetes) 
+ (.2683*pvd) 
+ (.1471*hypertn) + (.9331*(prpci=1 and 0<=priorpcitime<=365)) + (.2597*(prpci=1 and 
(priorpcitime<0 or priorpcitime>365))) 
+ (-.1061*(ClassNYH=2)) + (-.1073*(ClassNYH=3)) + (-.2120*(ClassNYH=4)) + 
(.0213*(admsxpre=2)) 
+ (.3403*(admsxpre=3)) + (.2720*(admsxpre=4)) + (.0871*(admsxpre=5)) + (-
.0515*(admsxpre=6)) 
+ (.1623*(PCIStat=2)) + (.6207*(PCIStat>=3)) + (.4765*(num_dis_ves>=2)) + 
(.1877*Ndilated) +  
+ (-.3908*(min_diam>=3)) + (.2795*(total_length>=30)); 
phat_des=exp(g_des)/(1+exp(g_des)); 
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nnt=1/(phat_bms-phat_des); 
 
DES_used=(num_des>0); 
/*exclusions*/ 
if num_des=. then ex=1; 
else if num_des>0 and num_bms>0 then ex=2; 
else if min_diam<2.5 then ex=3; 
else if max_diam>4 then ex=4; 
else if phat_bms=. then ex=5; 
else ex=0; 
run; 
 
proc freq data=tvr.data; 
tables ex; 
run; 
/*propensity model*/  
 
proc logistic data=tvr.data descending; 
where ex=0; 
class race gender payor tobacco classnyh admsxpre mlesscai pcistat; 
model des_used=age gender payor prchf prvalve diabetes renfail cvd pvd cld 
hypertn tobacco  hyprchol fhcad prpci prcab chf classnyh carshock admsxpre  
mlesscai mprestepr mpretimi mlesrisk min_diam total_length pcistat num_dis_ves; 
output out=pred p=ps_des xbeta=logit; 
run;  
 
data graph; 
set pred(keep=logit ps_des des_used); 
run; 
 
data graph; 
set graph; 
if des_used=0 then group=2*uniform(0); 
if des_used=1 then group=((2*uniform(0))+5); 
run; 
symbol1 height=.1 interpol=none value=dot color=black; 
axis1 value=('' 'BMS' '' '' '' '' 'DES' '') minor=none major=none; 
axis2 label=(a=90 'Logit DES') order=-5 to 6 by 1; 
title; 
 
proc gplot data=graph; 
plot logit*group/vaxis=axis2 haxis=axis1 vref=2.5 -2.5; 
run; 
quit; 
 
proc sort data=graph;by des_used;run; 
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proc capability data=graph; 
comphistogram logit/class=(des_used) 
     endpoints= -4 -3.5 -3 -2.5; 
run; 
quit; 
 
proc means max data=graph; 
var logit; 
run; 
 
%optimala(data=GRAPH,p=ps_des,group=des_used); 
 
/*optimal range (.075,.925)*/ 
data optimal; 
set pred; 
if 0<ps_des<.075 or ps_des>.925 then ex=6; 
run; 
 
proc freq data=optimal;tables ex;run; 
data tvr.final; 
set optimal; 
where ex=0; 
run; 
 
data tvr.final; 
set tvr.final; 
g_noangio=-2.6444+ (.2380*(age<=50)) + (-.3062*(age>=80)) + (.1848*diabetes) + 
(.2878*pvd) 
+ (.1759*hypertn) + (.7720*(prpci=1 and 0<=priorpcitime<=365)) + (.2265*(prpci=1 and 
(priorpcitime<0 or priorpcitime>365))) 
+ (.3694*prcab) + (-.0941*(ClassNYH=2)) + (-.0845*(ClassNYH=3)) + (-
.1853*(ClassNYH=4)) + (-.0643*(admsxpre=2)) 
+ (.2849*(admsxpre=3)) + (.2173*(admsxpre=4)) + (.0828*(admsxpre=5)) + (-
.1028*(admsxpre=6)) 
+ (.1497*(PCIStat=2)) + (.6204*(PCIStat>=3)); 
phat_bms_noangio=exp(g_noangio)/(1+exp(g_noangio)); 
 
/*phat groups spertus wants*/ 
if phat_bms<.1 then phat_group=1; 
else if .1<=phat_bms<.2 then phat_group=2; 
else if phat_bms>=.2 then phat_group=3; 
run; 
 
/*****random phys effect********/ 
proc glimmix data=model; 
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where pcioperatorkey^=-1 and num_proc>=100; 
class PCIOperatorKey; 
model des_used=phat100/dist=bin link=logit solution; 
nloptions tech=nrridg maxiter=1000; 
random intercept /subject=pcioperatorkey type=un solution g; 
ods output solutionr=random; 
covtest 'Ho: No random effects' ZeroG;  
run; 
 
/*********phat*time interaction test********/ 
proc glimmix data=time2 ; 
class time; 
model des_used=phat100|time/dist=poi link=log; 
*oddsratio phat100/at(time='1'); 
*oddsratio phat100/at(time='2'); 
estimate 'p overall' phat100 1/exp cl;  
estimate 'p early' phat100 1 phat100*time 1 0/exp cl; 
estimate 'p late' phat100 1 phat100*time 0 1/exp cl; 
lsmeans time/pdiff; 
run; 
 
   
 
